QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Signal Evaluation of GLP-1 Receptor Agonists and Acute Pancreatitis

Test your understanding of the concepts covered by Signal Evaluation: GLP-1 Receptor Agonists and Acute Pancreatitis.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why can raw increases in the number of pancreatitis reports be misleading?

Pancreatitis reports are never clinically valid The number of treated patients, exposure duration, reporting behaviour or patient characteristics may also have changed Spontaneous reports always exclude serious cases An increase in case counts automatically demonstrates increased incidence

Question 2 of 10 Which finding would tend to weaken, rather than strengthen, a causal interpretation of the pancreatitis signal?

The association disappears after adjustment for major baseline risk factors Cases recur after inadvertent rechallenge without alternative causes Several studies using appropriate active comparators show a consistent association A coherent exposure-response relationship is observed

Question 3 of 10 Which feature most improves the validity of an observational estimate of pancreatitis risk?

Using an unadjusted comparison with all untreated individuals Selecting an active comparator and addressing relevant baseline risk factors Counting only cases that appear in spontaneous reports Excluding patients with known pancreatitis risk factors from the treatment group only

Question 4 of 10 Which comparator would generally provide the most informative assessment of pancreatitis risk in an observational study of GLP-1 receptor agonists?

The entire general population Patients receiving a similar glucose-lowering treatment for a comparable indication Only patients who have never contacted healthcare services Patients selected because they already have pancreatitis

Question 5 of 10 Which statement best distinguishes biological plausibility from proof of causality?

A plausible mechanism establishes causality when spontaneous reports exist Receptor expression proves that therapeutic exposure causes pancreatic injury A plausible mechanism supports further investigation but does not demonstrate that the mechanism operates clinically at therapeutic exposure Mechanistic evidence is unnecessary when an adverse event is serious

Question 6 of 10 A QPPV sees a 30% increase in pancreatitis reports but learns that patient-years of exposure tripled during the same period. What is the most appropriate next step?

Conclude immediately that the risk increased by 30% Dismiss the increase because exposure grew Calculate and interpret reporting or incidence measures using appropriate exposure denominators and assess changes in reporting and case mix Assume the increase proves stimulated reporting

Question 7 of 10 Why is it important to distinguish direct pancreatic toxicity from indirect pathways involving gallstones?

Only direct toxicity can ever be considered in pharmacovigilance An association may arise through treatment-related changes such as weight loss and biliary disease rather than direct pancreatic injury Gallstones are not a recognised cause of pancreatitis Indirect pathways cannot contribute to regulatory decisions

Question 8 of 10 A positive disproportionality analysis for pancreatitis associated with one GLP-1 receptor agonist primarily indicates that:

The relative risk has been quantified Causality has been proven Further investigation is justified All products in the class should receive identical restrictions

Question 9 of 10 Which additional case feature would most strongly increase suspicion of an individual causal relationship, while still not establishing population-level incidence?

Recovery after discontinuation alone A recurrence of pancreatitis after inadvertent re-exposure in the absence of credible alternative causes The patient's awareness of media coverage about pancreatitis A diagnosis based only on a single nonspecific symptom

Question 10 of 10 Which statement best reflects the overall evidence-based conclusion of the case study?

Every episode of pancreatitis during GLP-1 receptor agonist therapy should be classified as caused by the medicine The signal was not worth investigating because patients with diabetes already have background risk The signal warranted regulatory attention and continued vigilance, but a uniform class-wide causal effect has not been established and alternative causes remain important Biological plausibility is sufficient to mandate withdrawal of the entire class

Knowledge Assessment: Signal Evaluation of GLP-1 Receptor Agonists and Acute Pancreatitis

Cookie Settings